Cybin : Corporate Presentation July 2025
CYBN.NE
Published on 07/01/2025 at 17:32
A Breakthrough Neuropsychiatry Company
Corporate Presentation
July 2025
NYSE American: CYBN Cboe CA: CYBN
1
Changing Minds: Redefining the Standard of Care in Mental Health
A Novel Treatment Approach to Neuropsychiatry
Cybin is developing differefiti6ted, fiext-gefier6tiofi ther6peutics with the potential to improve clifiic6l outcomes 6fid 6ddress key ufimet fieeds for people with mental health conditions1
Cybin is advancing ifitermittefit tre6tmefits with potential r6pid-ofiset, lofig-l6stifig clifiic6l effic6cy in treating depression and anxiety
Unlike current treatments that only address symptoms, our therapies t6rget ufiderlyifig
c6uses ifi fieur6l circuitry that lead to mental health disorders
Note:
3
Forward-looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation. Certain statements regarding psychedelic-based therapeutics have not been evaluated by the U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities, nor has the efficacy of psychedelic-based therapeutics been confirmed by approved research. There is no assurance that any of the Company's compounds will be used to diagnose, treat, cure or prevent any disease or condition and robust scientific research and clinical trials are needed. All such statements are subject to receipt of all necessary regulatory approvals from which all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Cybin is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocin and other analogues.
We Are an Advanced Clinical-Stage Neuropsychiatry Company Approaching Key Near-Term Milestones1
1
Two propriet6ry clifiic6l progr6ms, CYB003 6fid CYB004, targeting depression and anxiety disorders with positive Ph6se 2 s6fety 6fid effic6cy results
2
Lead program CYB003, which has been granted U.S. Food 6fid Drug Admifiistr6tiofi Bre6kthrough Ther6py Desigfi6tiofi is ifi Ph6se 3 developmefit for the 6djufictive tre6tmefit of M6jor Depressive Disorder ("MDD")
3
Robust pipelifie of differefiti6ted 6ssets with potential for expansion into 6dditiofi6l fieuropsychi6try ifidic6tiofis with high ufimet fieed 6ffectifig >200M people ifi the U.S.2
4
Strofig Ifitellectu6l Property Portfolio:
over 90 granted patents, over 230 patent applications pending
5
Well-C6pit6lized to move programs forward with cash position of
C$135 milliofi as of March 31, 2025
Notes:
4
Forward looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to Cybin. Such statements are informed by, among other things, regulatory guidelines for developing a drug with timeline safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and Cybin's development efforts to date.
Addressable market is estimated based on U.S. census population of 337,049,203 as of September 8, 2024 and on U.S. prevalence of indications including depression, anxiety disorders/PTSD, bipolar disorder, substance use/addiction disorders, eating disorders, cluster headaches/migraine, and chronic pain management
Exceptional Team Pedigree With Successful Track Record of Bringing Drugs to Market1
Doug Drysdale Chief Executive Officer
Tom Macek SVP, Clinical Development
Amir Inamdar MBBS, DNB(Psych),FFPM
Chief Medical Officer
Atul R. Mahableshwarkar, M.D., DLFAPA
SVP, Clinical Development
Alex Nivorozhkin, Ph.D
Chief Scientific Officer
Allison
House-Gecewicz SVP, Clinical Operations
Aaron Bartlone Chief Operating Officer
Geoff Varty
Ph.D.
Head of R&D
Combined 60 Investigational New Drug (IND) applications, 37 exits
Combined 300 peer-reviewed publications by scientific leadership
Note:
5
TRINTELLIX, CELEXA, and LEXAPRO are registered trademarks of H. Lundbeck A/S (aktieselskap; DENMARK); NAMENDA is a registered trademark of MERZ PHARMA GMBH & CO. KGAA (KGAA; GERMANY); SABRIL is a registered trademark of Lundbeck LLC (LIMITED LIABILITY COMPANY; DELAWARE, USA); ALLEGRA is a registered trademark of Aventisub LLC (LIMITED LIABILITY COMPANY; DELAWARE, USA); ANZEMET is a registered trademark of VALIDUS PHARMACEUTICALS LLC (LIMITED LIABILITY COMPANY; DELAWARE, USA); LATUDA is a registered trademark of SUMITOMO PHARMA CO., LTD. (CORPORATION; JAPAN); ROZEREM is a registered trademark of Takeda Pharmaceutical Company Limited (CORPORATION; JAPAN); VANIQA is a registered trademark of ALLERGAN, INC. (CORPORATION; DELAWARE, USA); ZOLGENSMA is a registered trademark of NOVARTIS AG (Aktiengesellschaft; SWITZERLAND); SAPHRIS is a registered trademark of N.V. ORGANON (NAAMLOZE VENNOOTSCHAP (NV); NETHERLANDS).
Disclaimer
Cybin Inc. published this content on July 01, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 01, 2025 at 21:31 UTC.